Pacira BioSciences (NASDAQ:PCRX - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "strong-buy" rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other equities research analysts have also recently issued reports on PCRX. JPMorgan Chase & Co. upgraded Pacira BioSciences from an "underweight" rating to a "neutral" rating and set a $36.50 price target for the company in a research note on Thursday, October 8th. Leerink Partners began coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They set a "market perform" rating and a $28.00 price objective on the stock. Zacks Research raised Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 3rd. Weiss Ratings upgraded Pacira BioSciences from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, November 9th. Finally, Royal Bank Of Canada upped their target price on Pacira BioSciences from $25.00 to $36.50 and gave the company a "sector perform" rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $33.33.
View Our Latest Research Report on PCRX
Pacira BioSciences Price Performance
PCRX opened at $36.48 on Friday. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $36.67. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.65 and a current ratio of 4.68. The company has a market capitalization of $1.46 billion, a P/E ratio of 39.23 and a beta of 0.21. The stock has a fifty day moving average of $32.26 and a 200-day moving average of $26.01.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by ($0.05). Pacira BioSciences had a net margin of 5.08% and a return on equity of 11.91%. The business had revenue of $176.65 million during the quarter, compared to the consensus estimate of $181.94 million. On average, equities analysts expect that Pacira BioSciences will post 1.90 EPS for the current year.
Insider Buying and Selling at Pacira BioSciences
In other news, SVP Lauren Riker sold 6,000 shares of the company's stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the completion of the transaction, the senior vice president directly owned 62,284 shares in the company, valued at approximately $2,262,154.88. This represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in PCRX. Hantz Financial Services Inc. lifted its position in shares of Pacira BioSciences by 39.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,571 shares of the company's stock worth $39,000 after purchasing an additional 448 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Pacira BioSciences during the second quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pacira BioSciences during the third quarter worth about $51,000. State of Wyoming purchased a new stake in Pacira BioSciences in the 2nd quarter valued at $78,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Pacira BioSciences by 15.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company's stock worth $85,000 after buying an additional 492 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira BioSciences is a biopharmaceutical company focused on non-opioid approaches to pain management and related health needs. Its portfolio includes medicines and a device intended for use in surgical, musculoskeletal and other care settings. The company's products include EXPAREL, a long-acting bupivacaine formulation used for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis pain; and the iovera system, which uses targeted cold to temporarily block peripheral nerves and relieve pain.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.